Clinical course of neurological disorders in experimental hemorrhagic stroke after treatment with interleukin-2 (ronkoleukinum)

E V Suprun; N A But; S V Tereshchenko

doi:10.17816/KMJ1984

Kazan medical journal ›› 2014, Vol. 95 ›› Issue (6) : 801 -806. DOI: 10.17816/KMJ1984

Theoretical and clinical medicine

research-article

Clinical course of neurological disorders in experimental hemorrhagic stroke after treatment with interleukin-2 (ronkoleukinum)

Author information +

History +

PDF

Abstract

Aim. To study the influence of recombinant interleukin-2 (Ronkoleukinum) on indicators of oxidative protein modification and severity of neurologic signs in rats with experimental hemorrhagic stroke. Methods. Oxidative protein modification (by aldehyde and carboxyl products), the survival rate, neurological deficit by McGrow Stroke-index and animal psychophysiological status were studied on the model of intracerebral hemorrhage in rats after treatment with 0.01 mg/kg of interleukin-2 (Ronkoleukinum). Results. The progression of experimental hemorrhagic stroke in rats was accompanied with typical pathophysiological signs - oxidative protein modification with following neurological and cognitive disorders, followed by death of experimental animals. Administration of interleukin-2 (Ronkoleukinum) 0.01 mg/kg hampered the processes of free radical proteins damage, therefore decreasing the mortality rate in animals with intracerebral hemorrhage. Animals that were administered interleukin-2 (Ronkoleukinum) died only during the first 24 hours after the stroke, with mortality rate significantly lower compared to controls starting form the 4th day of the experiment (р <0.05). The use of interleukin-2 (Ronkoleukinum) also statistically significantly decreased the severity of post-ischemic behavioral, neurological and cognitive disorders, improving the movement activity, psychoneurological status assessed by McGrow scale, stabilizing the memory and passive avoidance reflex recovery. Conclusion: interleukin-2 (Ronkoleukinum) can effectively prevent the formation of post-stroke neuronal disorders, so its use as a nosotropic nootropic agent seems to have a good perspective.

Keywords

interleukin-2 / Ronkoleukinum / experimental hemorrhagic stroke

Cite this article

Download citation ▾

E V Suprun, N A But, S V Tereshchenko. Clinical course of neurological disorders in experimental hemorrhagic stroke after treatment with interleukin-2 (ronkoleukinum). Kazan medical journal, 2014, 95(6): 801-806 DOI:10.17816/KMJ1984

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Арушанян Э.Б., Бейер Э.В. Гиппокамп и нарушения познавательной деятельности // Ж. неврол. и психиатр. им. С.С. Корсакова. - 2007. - №7. - С. 72-77.

[2]	Беридзе М.З., Урушадзе И.Т., Шакаришвили Р.Р. Механизмы отсроченной гибели нейронов при острой церебральной ишемии в эксперименте // Ж. неврол. и психиатр. им. С.С. Корсакова. Инсульт (приложение). - 2001. - №3. - С. 35-40.

[3]	Виленский Б.С. Инсульт: профилактика, диагностика и лечение. - СПб: Фолиант, 2002. - 397 с.

[4]	Губский Ю.И., Беленичев И.Ф., Павлов С.В. и др. Токсикологические последствия окислительной модификации белков при различных патологических состояниях (обзор литературы) // Совр. пробл. токсикол. - 2005. - №3. - С. 20-26.

[5]	Гусев Е.И., Скворцова В.И. Ишемия головного мозга. - М.: Медицина, 2001. - 328 с.

[6]	Завалишин И.А., Захарова М.Н. Гибель нейрона - кардинальная проблема неврологии и психиатрии // Вестн. РАМН. - 2000. - №2. - С. 28-33.

[7]	Козлов В.К. Сепсис: этиология, иммунопатогенез, концепция современной иммунотерапии. - Киев: АННА-Т, 2007. - 296 с.

[8]	Лурия А.Р. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. - М.: Медицина, 2000. - 287 с.

[9]	Сазонтова Т.Г., Жукова А.Г., Анчишкина Н.А., Архипенко Ю.В. Фактор транскрипции HIF-1α, белки срочного ответа и резистентность мембранных структур в динамике после острой гипоксии // Вестн. РАМН. - 2007. - №2. - С. 17-25.

[10]	Симбирцев А.С. Цитокины: классификация и биологические функции // Цитокины и воспаление. - 2004. - Т. 3, №2. - С. 16-22.

[11]	Скворцова В.И. Механизмы повреждающего действия церебральной ишемии и новые терапевтические стратегии // Инсульт. - 2003. - №9. - С. 20-22.

[12]	Arend W.P. The balance between IL-1 and IL-1Ra in disease // Cytokine Growth Factor Rev. - 2002. - Vol. 13 (4-5). - P. 323-340.

[13]	Kehrer J.P. Cause-effect of oxidative stress and apoptosis // Teratology. - 2000. - Vol. 62. - P. 235-246.

[14]	Kim H. M., Shin H.Y., Jeong H.J. et al. Reduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage // J. Mol. Neurosci. - 2000. - Vol. 14 (3). - P. 191-196.

[15]	Pulsinelli W.A. Selective neuronal vulnerability: morphological and molecular characterestics // Progr. Brain Res. - 1985. - Vol. 53. - Р. 29-37.